{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T07:53:44Z","timestamp":1787644424370,"version":"build-2736575974"},"reference-count":83,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jbspin.2025.105943","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T03:18:25Z","timestamp":1751426305000},"page":"105943","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Residual disease in axial spondyloarthritis. Facts and issues"],"prefix":"10.1016","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4687-5780","authenticated-orcid":false,"given":"Daniel","family":"Wendling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Goupille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Verhoeven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Prati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2025.105943_bib0420","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0140-6736(24)02263-3","article-title":"Axial spondyloarthritis","volume":"405","author":"Navarro-Comp\u00e1n","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2025.105943_bib0425","doi-asserted-by":"crossref","first-page":"105344","DOI":"10.1016\/j.jbspin.2022.105344","article-title":"2022 French Society for Rheumatology (SFR) recommendations on the everyday management of patients with spondyloarthritis, including psoriatic arthritis","volume":"89","author":"Wendling","year":"2022","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2025.105943_bib0430","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1093\/rheumatology\/keaa268","article-title":"Effect of biologic disease-modifying anti-rheumatic drugs targeting remission in axial spondyloarthritis: systematic review and meta-analysis","volume":"59","author":"Cruz-Machado","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2025.105943_bib0435","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.3899\/jrheum.220459","article-title":"One-third of European patients with axial spondyloarthritis reach pain remission with routine care tumor necrosis factor inhibitor treatment","volume":"50","author":"\u00d8rnbjerg","year":"2023","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2025.105943_bib0440","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1007\/s00296-024-05576-7","article-title":"Disease activity and widespread pain are main contributors to patient-reported global health in axial spondyloarthritis: an analysis of 6064 patients","volume":"44","author":"Drouet","year":"2024","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jbspin.2025.105943_bib0445","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jbspin.2013.01.003","article-title":"Evaluation of spondylarthritis activity by patients and physicians: ASDAS, BASDAI, PASS, and flares in 200 patients","volume":"80","author":"Godfrin-Valnet","year":"2013","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2025.105943_bib0450","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/rheumatology\/kead155","article-title":"Treatment decisions in axial spondyloarthritis daily clinical practice are more than treat-to-target","volume":"63","author":"Bolt","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2025.105943_bib0455","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1007\/s10067-021-06018-6","article-title":"Presence of subclinical inflammation in axial spondyloarthritis patients with NSAID\/anti-TNF-\u03b1 drug-induced clinical remission","volume":"41","author":"Zong","year":"2022","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2025.105943_bib0460","doi-asserted-by":"crossref","first-page":"e004369","DOI":"10.1136\/rmdopen-2024-004369","article-title":"Exploratory analysis of the potential disconnect between objective inflammatory response and clinical response following certolizumab pegol treatment in patients with active axial spondyloarthritis","volume":"10","author":"Rudwaleit","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2025.105943_bib0465","doi-asserted-by":"crossref","first-page":"103423","DOI":"10.1016\/j.autrev.2023.103423","article-title":"Residual pain in rheumatoid arthritis: is it a real problem?","volume":"22","author":"Sarzi-Puttini","year":"2023","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jbspin.2025.105943_bib0470","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s40744-022-00443-y","article-title":"Residual disease associated with suboptimal treatment response in patients with psoriatic arthritis: a systematic review of real-world evidence","volume":"9","author":"Coates","year":"2022","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.jbspin.2025.105943_bib0475","doi-asserted-by":"crossref","first-page":"105372","DOI":"10.1016\/j.jbspin.2022.105372","article-title":"Residual patient-reported burden in 444 patients with psoriatic arthritis in remission or low disease: a cross-sectional analysis","volume":"89","author":"Lucasson","year":"2022","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2025.105943_bib0480","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00296-018-4201-3","article-title":"Residual symptoms and disease burden among patients with psoriatic arthritis: is a new disease activity index required?","volume":"39","author":"Kilic","year":"2019","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jbspin.2025.105943_bib0485","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1136\/annrheumdis-2020-218480","article-title":"Axial involvement in patients with early peripheral spondyloarthritis: a prospective MRI study of sacroiliac joints and spine","volume":"80","author":"Renson","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2025.105943_bib0490","first-page":"354","article-title":"Presence of subclinical inflammation in axial spondyloarthropathy patients in clinical remission","volume":"96","author":"Wu","year":"2016","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"10.1016\/j.jbspin.2025.105943_bib0495","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13075-018-1556-5","article-title":"Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial","volume":"20","author":"van der Heijde","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2025.105943_bib0500","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3899\/jrheum.200934","article-title":"Residual disease burden in patients with axial spondyloarthritis and psoriatic arthritis despite low disease activity states in a multiethnic Asian population","volume":"48","author":"Liu","year":"2021","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2025.105943_bib0505","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.3390\/jcm11123553","article-title":"Residual disease in patients with axial spondyloarthritis: a post-hoc analysis of the QUASAR study","volume":"11","author":"D\u2019Angelo","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.jbspin.2025.105943_bib0510","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.3899\/jrheum.2023-0194","article-title":"Factors associated with residual disease in axial spondyloarthritis: results from a clinical practice registry","volume":"50","author":"Webers","year":"2023","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2025.105943_bib0515","first-page":"987","article-title":"Assessment of residual symptoms in patients with axial spondyloarthritis with low disease activity and analysis of its related factors","volume":"56","author":"Zhai","year":"2024","journal-title":"Beijing Da Xue Xue Bao Yi Xue Ban"},{"key":"10.1016\/j.jbspin.2025.105943_bib0520","doi-asserted-by":"crossref","first-page":"e004009","DOI":"10.1136\/rmdopen-2023-004009","article-title":"Association of nociplastic and neuropathic pain components with the presence of residual symptoms in patients with axial spondyloarthritis receiving biological disease-modifying antirheumatic drugs","volume":"10","author":"Al Mohamad","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2025.105943_bib0525","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1002\/acr.25103","article-title":"Influence of sex on early axial spondyloarthritis: a six-year longitudinal analysis from a large national cohort","volume":"75","author":"Aouad","year":"2023","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jbspin.2025.105943_bib0530","doi-asserted-by":"crossref","first-page":"e15433","DOI":"10.1111\/1756-185X.15433","article-title":"Females with axial spondyloarthritis have longer diagnostic delay and higher burden of the disease. Results from the International Map of Axial Spondyloarthritis (IMAS)","volume":"27","author":"Navarro-Comp\u00e1n","year":"2024","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.jbspin.2025.105943_bib0535","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/acr.25436","article-title":"Low socioeconomic status and female sex are associated with worse functional status in axial spondyloarthritis","volume":"77","author":"Stovall","year":"2025","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jbspin.2025.105943_bib0540","doi-asserted-by":"crossref","DOI":"10.1002\/acr.25512","article-title":"Sex-related differences in efficacy and safety outcomes in axial spondyloarthritis randomized clinical trials: a systematic literature review and meta-analysis","author":"Gao","year":"2025","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jbspin.2025.105943_bib0545","doi-asserted-by":"crossref","first-page":"105420","DOI":"10.1016\/j.jbspin.2022.105420","article-title":"Tender to touch-prevalence and impact of concomitant fibromyalgia and enthesitis in spondyloarthritis: an ancillary analysis of the ASAS PerSpA study","volume":"89","author":"Fitzgerald","year":"2022","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2025.105943_bib0550","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/BOR.0000000000001023","article-title":"Navigating the complexity of pain in psoriatic arthritis and axial spondyloarthritis","volume":"36","author":"Mease","year":"2024","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jbspin.2025.105943_bib0555","doi-asserted-by":"crossref","first-page":"e001326","DOI":"10.1136\/rmdopen-2020-001326","article-title":"Part of pain labelled neuropathic in rheumatic disease might be rather nociplastic","volume":"6","author":"Bailly","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2025.105943_bib0560","doi-asserted-by":"crossref","first-page":"1341981","DOI":"10.3389\/fimmu.2024.1341981","article-title":"Pain in axial spondyloarthritis: role of the JAK\/STAT pathway","volume":"15","author":"Selmi","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.jbspin.2025.105943_bib0565","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1093\/rheumatology\/keac679","article-title":"The natural history of chronic widespread pain in patients with axial spondyloarthritis: a cohort study with clinical and self-tracking data","volume":"62","author":"Soni","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2025.105943_bib0570","doi-asserted-by":"crossref","first-page":"4476","DOI":"10.1093\/rheumatology\/keab019","article-title":"Central sensitization, illness perception and obesity should be considered when interpreting disease activity in axial spondyloarthritis","volume":"60","author":"Kieskamp","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2025.105943_bib0575","doi-asserted-by":"crossref","first-page":"151933","DOI":"10.1016\/j.semarthrit.2021.11.006","article-title":"Central sensitization has major impact on quality of life in patients with axial spondyloarthritis","volume":"52","author":"Kieskamp","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2025.105943_bib0580","doi-asserted-by":"crossref","first-page":"176","DOI":"10.4078\/jrd.2023.0009","article-title":"The effect of central sensitization on disease activity measures, quality of life and clinical parameters in axial spondyloarthritis: a cross-sectional study","volume":"30","author":"\u015ea\u015f","year":"2023","journal-title":"J Rheum Dis"},{"key":"10.1016\/j.jbspin.2025.105943_bib0585","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s00296-023-05317-2","article-title":"Biopsychosocial factors should be considered when evaluating central sensitization in axial spondyloarthritis","volume":"43","author":"Sariyildiz","year":"2023","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jbspin.2025.105943_bib0590","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X20966123","article-title":"Comorbid pain in axial spondyloarthritis, including fibromyalgia","volume":"12","author":"L\u00f3pez-Medina","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.jbspin.2025.105943_bib0595","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/annrheumdis-2017-212378","article-title":"Evaluation of the impact of concomitant fibromyalgia on TNF alpha blockers\u2019 effectiveness in axial spondyloarthritis: results of a prospective, multicentre study","volume":"77","author":"Molt\u00f3","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2025.105943_bib0600","first-page":"1856","article-title":"The negative impact of pain catastrophising on disease activity: analyses of data derived from patient-reported outcomes in psoriatic arthritis and axial spondyloarthritis","volume":"41","author":"Currado","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2025.105943_bib0605","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13075-024-03396-5","article-title":"Pain catastrophizing negatively impacts drug retention rate in patients with Psoriatic Arthritis and axial Spondyloarthritis: results from a 2-years perspective multicenter GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica) study","volume":"26","author":"Currado","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2025.105943_bib0610","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s10067-021-05953-8","article-title":"Prevalence of sleep disturbance and the association between poor disease control in people with ankylosing spondylitis within the Australian clinical setting (ASLEEP study): a real-world observational study using the OPAL dataset","volume":"41","author":"Tymms","year":"2022","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2025.105943_bib0615","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s42358-025-00439-6","article-title":"Correlates of depression, anxiety, and stress among patients with ankylosing spondylitis","volume":"65","author":"Yang","year":"2025","journal-title":"Adv Rheumatol"},{"key":"10.1016\/j.jbspin.2025.105943_bib0620","doi-asserted-by":"crossref","first-page":"5734","DOI":"10.1093\/rheumatology\/keab242","article-title":"Depression and anxiety symptoms at TNF inhibitor initiation are associated with impaired treatment response in axial spondyloarthritis","volume":"60","author":"Zhao","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2025.105943_bib0625","doi-asserted-by":"crossref","first-page":"e000657","DOI":"10.1136\/rmdopen-2018-000657","article-title":"Prevalence of degenerative changes and overlap with spondyloarthritis-associated lesions in the spine of patients from the DESIR cohort","volume":"4","author":"de Bruin","year":"2018","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2025.105943_bib0630","doi-asserted-by":"crossref","first-page":"105899","DOI":"10.1016\/j.jbspin.2025.105899","article-title":"Muscle in axial spondyloarthritis: culprit or victim?","volume":"2","author":"Wendling","year":"2025","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2025.105943_bib0635","doi-asserted-by":"crossref","first-page":"105873","DOI":"10.1016\/j.jbspin.2025.105873","article-title":"Prevalence and associations of kinesiophobia with patient reported outcomes and mobility measures in axial spondyloarthritis","volume":"92","author":"Kiefer","year":"2025","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2025.105943_bib0640","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X20972610","article-title":"The impact of extra-musculoskeletal manifestations on disease activity, functional status, and treatment patterns in patients with axial spondyloarthritis: results from a nationwide population-based study","volume":"12","author":"Redeker","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"10.1016\/j.jbspin.2025.105943_bib0645","doi-asserted-by":"crossref","first-page":"e003461","DOI":"10.1136\/rmdopen-2023-003461","article-title":"Difficult-to-treat axial spondyloarthritis is associated with psoriasis, peripheral involvement and comorbidities: results of an observational nationwide study","volume":"9","author":"Fakih","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2025.105943_bib0650","doi-asserted-by":"crossref","first-page":"101857","DOI":"10.1016\/j.berh.2023.101857","article-title":"The association between comorbidities and disease activity in spondyloarthritis - a narrative review","volume":"37","author":"Bosch","year":"2023","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.jbspin.2025.105943_bib0655","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1007\/s40265-024-02100-w","article-title":"Difficult-to-treat axial spondyloarthritis: a new challenge","volume":"84","author":"Wendling","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.jbspin.2025.105943_bib0660","doi-asserted-by":"crossref","first-page":"105512","DOI":"10.1016\/j.jbspin.2022.105512","article-title":"Is the difficult-to-treat (D2T) concept applicable to axial spondyloarthritis?","volume":"90","author":"Wendling","year":"2023","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2025.105943_bib0665","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.ard.2025.01.035","article-title":"The Assessment of SpondyloArthritis International Society (ASAS) consensus-based expert definition of difficult-to-manage, including treatment-refractory, axial spondyloarthritis","volume":"84","author":"Poddubnyy","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2025.105943_bib0670","doi-asserted-by":"crossref","first-page":"105770","DOI":"10.1016\/j.jbspin.2024.105770","article-title":"Navigating the complexities of difficult-to-treat axial spondyloarthritis","volume":"91","author":"Ribeiro","year":"2024","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2025.105943_bib0675","first-page":"971","article-title":"Clinical relevance of C-reactive protein in axial involvement of ankylosing spondylitis","volume":"26","author":"Dougados","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2025.105943_bib0680","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1093\/rheumatology\/kep393","article-title":"Clinical relevance of C-reactive protein in ankylosing spondylitis and evaluation of the NSAIDs\/coxibs\u2019 treatment effect on C-reactive protein","volume":"49","author":"Benhamou","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2025.105943_bib0685","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/1744666X.2024.2400294","article-title":"Nociplastic pain in axial spondyloarthritis and psoriatic arthritis: role of JAK kinases in immunopathology and therapeutic impact of JAK inhibitors","volume":"21","author":"Horbal","year":"2025","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.jbspin.2025.105943_bib0690","doi-asserted-by":"crossref","first-page":"105741","DOI":"10.1016\/j.jbspin.2024.105741","article-title":"Unmet needs in axial spondyloarthritis. Proceedings of the French spondyloarthritis taskforce workshop","volume":"91","author":"Wendling","year":"2024","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2025.105943_bib0695","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1185\/03007995.2016.1157460","article-title":"The painDETECT project\u00a0\u2013\u00a0far more than a screening tool on neuropathic pain","volume":"32","author":"Freynhagen","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jbspin.2025.105943_bib0700","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/acr.20140","article-title":"The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity","volume":"62","author":"Wolfe","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jbspin.2025.105943_bib0705","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1533-2500.2011.00493.x","article-title":"The development and psychometric validation of the central sensitization inventory","volume":"12","author":"Mayer","year":"2012","journal-title":"Pain Pract"},{"key":"10.1016\/j.jbspin.2025.105943_bib0710","doi-asserted-by":"crossref","first-page":"e004528","DOI":"10.1136\/rmdopen-2024-004528","article-title":"Value of the central sensitisation inventory in patients with axial spondyloarthritis","volume":"10","author":"van der Kraan","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2025.105943_bib0715","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.pain.2010.03.034","article-title":"CEDR (Cercle d\u2019Etude de la Douleur en Rhumatologie). Development and validation of the Fibromyalgia Rapid Screening Tool (FiRST)","volume":"150","author":"Perrot","year":"2010","journal-title":"Pain"},{"key":"10.1016\/j.jbspin.2025.105943_bib0720","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.jbspin.2025.105943_bib0725","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1037\/1040-3590.7.4.524","article-title":"The pain catastrophizing scale: development and validation","volume":"7","author":"Sullivan","year":"1995","journal-title":"Psychol Assess"},{"key":"10.1016\/j.jbspin.2025.105943_bib0730","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1136\/annrheumdis-2013-203967","article-title":"Development of a health index in patients with ankylosing spondylitis (ASAS HI): final result of a global initiative based on the ICF guided by ASAS","volume":"74","author":"Kiltz","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2025.105943_bib0735","doi-asserted-by":"crossref","first-page":"e002280","DOI":"10.1136\/rmdopen-2022-002280","article-title":"Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension","volume":"8","author":"van der Heijde","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2025.105943_bib0740","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s13075-024-03412-8","article-title":"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis refractory to biologic therapy: 2-year clinical and radiographic results from the open-label extension of the SELECT-AXIS 2 study","volume":"26","author":"Baraliakos","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jbspin.2025.105943_bib0745","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0140-6736(22)01212-0","article-title":"Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"400","author":"Deodhar","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2025.105943_bib0750","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2147\/JIR.S219586","article-title":"JAK inhibitors in rheumatoid arthritis: an evidence-based review on the emerging clinical data","volume":"13","author":"Harrington","year":"2020","journal-title":"J Inflamm Res"},{"key":"10.1016\/j.jbspin.2025.105943_bib0755","doi-asserted-by":"crossref","first-page":"831","DOI":"10.3390\/jcm8060831","article-title":"Achieving pain control in rheumatoid arthritis with baricitinib or adalimumab plus methotrexate: results from the RA-BEAM trial","volume":"8","author":"Taylor","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.jbspin.2025.105943_bib0760","doi-asserted-by":"crossref","first-page":"e003839","DOI":"10.1136\/rmdopen-2023-003839","article-title":"Impact of filgotinib on pain control in the phase 3 FINCH studies","volume":"10","author":"Taylor","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2025.105943_bib0765","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1136\/annrheumdis-2019-215764","article-title":"Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response","volume":"78","author":"Fleischmann","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2025.105943_bib0770","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.3390\/ijms23031246","article-title":"Janus kinase inhibitors improve disease activity and patient-reported outcomes in rheumatoid arthritis: a systematic review and meta-analysis of 24,135 patients","volume":"23","author":"T\u00f3th","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jbspin.2025.105943_bib0775","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/art.43014","article-title":"Effectiveness of JAK inhibitors compared with biologic disease-modifying antirheumatic drugs on pain reduction in rheumatoid arthritis: results from a nationwide Swedish cohort study","volume":"77","author":"Eberhard","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2025.105943_bib0780","doi-asserted-by":"crossref","first-page":"999407","DOI":"10.3389\/fimmu.2022.999407","article-title":"Interleukin-17 as a potential therapeutic target for chronic pain","volume":"13","author":"Jiang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jbspin.2025.105943_bib0785","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s40122-024-00603-8","article-title":"Tumor necrosis factor and interleukin modulators for pathologic pain states: a narrative review","volume":"13","author":"Kaye","year":"2024","journal-title":"Pain Ther"},{"key":"10.1016\/j.jbspin.2025.105943_bib0790","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s40744-024-00660-7","article-title":"Exploring the effects of ixekizumab on pain in patients with ankylosing spondylitis based on objective measures of inflammation: post hoc analysis from a large randomized clinical trial","volume":"11","author":"de Vlam","year":"2024","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.jbspin.2025.105943_bib0795","first-page":"260","article-title":"Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C-reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2-year data from the MEASURE 2 study","volume":"37","author":"Deodhar","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2025.105943_bib0800","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1093\/rheumatology\/keae549","article-title":"Impact of treatments on fatigue in axial spondyloarthritis: a systematic review and meta-analysis","volume":"64","author":"Delcourt","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2025.105943_bib0805","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1136\/ard-2022-223297","article-title":"Efficacy and safety of non-pharmacological and non-biological interventions: a systematic literature review informing the 2022 update of the ASAS\/EULAR recommendations for the management of axial spondyloarthritis","volume":"82","author":"Ortolan","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2025.105943_bib0810","doi-asserted-by":"crossref","first-page":"105750","DOI":"10.1016\/j.jbspin.2024.105750","article-title":"Chronic pain for rheumatological disorders: pathophysiology, therapeutics and evidence","volume":"91","author":"Chen","year":"2024","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2025.105943_bib0815","doi-asserted-by":"crossref","first-page":"103357","DOI":"10.1016\/j.autrev.2023.103357","article-title":"Effect of body mass index on treatment response of biologic\/targeted-synthetic DMARDs in patients with rheumatoid arthritis, psoriatic arthritis or axial spondyloarthritis: a systematic review","volume":"22","author":"Gialouri","year":"2023","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jbspin.2025.105943_bib0820","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.semarthrit.2015.08.003","article-title":"Exercise for ankylosing spondylitis: an evidence-based consensus statement","volume":"45","author":"Millner","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2025.105943_bib0825","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1093\/rheumatology\/keaf102","article-title":"Interrelationships of disease activity, central sensitization, psychosocial and lifestyle factors in axial spondyloarthritis","volume":"64","author":"Kieskamp","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2025.105943_bib0830","doi-asserted-by":"crossref","first-page":"rkaa063","DOI":"10.1093\/rap\/rkaa063","article-title":"Feasibility, acceptability and change in health following a telephone-based cognitive behaviour therapy intervention for patients with axial spondyloarthritis","volume":"5","author":"Pedley","year":"2020","journal-title":"Rheumatol Adv Pract"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X25001058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X25001058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T15:41:35Z","timestamp":1767800495000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X25001058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":83,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1297319X25001058"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2025.105943","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Residual disease in axial spondyloarthritis. Facts and issues","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2025.105943","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 Fran\u00e7aise de Rhumatologie.","name":"copyright","label":"Copyright"}],"article-number":"105943"}}